Nanjing Hairong Pharmaceutical

Nanjing Hairong Pharmaceutical is a Chinese pharmaceutical company specializing in the development and manufacturing of small molecule drugs, with a focus on cardiovascular, analgesic, and oncology treatments. Since 2020, it has operated as a subsidiary of Nanjing King-Friend Biochemical Pharmaceutical, a major player in the heparin and injectable drug markets. The company is best known for its antiplatelet drug Indobufen, which is widely used in China for cardiovascular indications. Nanjing Hairong maintains a robust R&D pipeline featuring several clinical-stage candidates, including novel analgesics and anti-tumor agents. Its facilities in Nanjing are GMP-certified, supporting both its internal pipeline and commercial production needs.